PCI Pharma Services has acquired an entire equity stake in Ajinomoto Althea, Inc. ("Althea"), a US-based sterile fill-finish CDMO and 100% subsidiary of Japan-based Ajinomoto Co., Inc. Scheduled for completion in May 2025

The acquisition creates a world-class large-scale manufacturing hub in San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high potent formulations such as ADCs, complementing existing global sterile fill-finish and advanced drug delivery operations.

Althea's robust clinical and commercial-stage services for injectable drug products augments PCI deep industry experience, aligning with the company's global sterile fill-finish capabilities and established expertise in advanced drug delivery. In addition, Althea's substantial knowledge base, skillsets and capacity in scalable, custom oligonucleotides and peptides complements our existing manufacturing capabilities in complex formulations and lyophilization across a broad range of injectables - including nanoparticles, mRNA, MABs, proteins, and other biologics for delivery formats such as vials, bottles, prefilled syringes and autoinjectors.

The acquisition also adds high potent vial filling with lyophilization, making us one of very few US-based CDMOs capable of producing the emerging oncology modality of antibody-drug conjugates (ADCs). Building upon PCI's legacy in high potent molecules, the strategy creates an end-to-end offering for clients via specialized capabilities across the globe, and broadens its biologics development and manufacturing leadership.

For our advanced drug delivery systems and drug-device combination business, Althea's assets supplement our leadership position in final device assembly and packaging facilities in both Europe and North America.

Acquiring Althea's San Diego campus also makes us one of the largest manufacturing centers in the US West Coast's biopharma stronghold and is a natural extension of our current clinical trial services and early phase robotic sterile fill-finish capabilities, creating a scalable, flexible manufacturing complex with state-of-the-art facilities within minutes of each other.

"To continue supporting the needs of our customers in their endeavors to bring life-changing therapies to patients, PCI continues to make sizable investments in the sterile fill-finish category that bring additional capabilities, capacity and technologies into our portfolio," said Salim Haffar, CEO of PCI Pharma Services. "Welcoming Althea into the PCI family expands our capabilities to support several therapeutic and drug delivery modalities, including the emerging ADC marketplace, and complements our broad end-to-end solutions alongside clinical trial services and advanced drug delivery."

In September 2025, PCI announced investments of more than $365 million in infrastructure supporting the clinical and commercial-scale final assembly and packaging of drug-device combination products utilizing advanced drug delivery systems, with an emphasis on injectable formats. Including new and expanded facilities in both Europe and North America,

Highlights include investment in the Philadelphia biotech facility, acquisition of a new pharma device assembly and packaging facility near Dublin, Ireland, and a new Center of Excellence for advanced drug delivery and drug-device combination product assembly and packaging in Rockford, Illinois.

In the United States, PCI has plans for an ambitious 545,000-square-foot expansion at its campus in Rockford, Illinois, dedicated to advanced drug delivery and drug-device combination assembly and packaging